Statements (58)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:monoclonal_antibody
|
gptkbp:analysis |
ongoing
|
gptkbp:business_model |
approved by ethics committees
|
gptkbp:class |
gptkb:immunotherapy
|
gptkbp:clinical_trial |
gptkb:2016
Phase 1 multiple countries overall response rate pending publication Phase 1 and beyond NCT02830063 |
gptkbp:collaboration |
clinical research organizations
|
gptkbp:collaborations |
with academic institutions
with other pharmaceutical companies |
gptkbp:developed_by |
gptkb:Abb_Vie
|
gptkbp:dosage_form |
based on clinical trial protocol
|
gptkbp:duration |
depends on response
|
gptkbp:efficacy_data |
preliminary results available
|
gptkbp:eligibility |
varies by trial
|
gptkbp:feedback |
collected during trials
|
gptkbp:funding |
provided by Abb Vie
|
gptkbp:future_prospects |
planned for combination therapies
|
https://www.w3.org/2000/01/rdf-schema#label |
ABBV-181
|
gptkbp:impact |
potential to improve outcomes
|
gptkbp:invention |
patented
|
gptkbp:investigator_initiated_trials |
may occur
|
gptkbp:is_monitored_by |
required during treatment
|
gptkbp:is_tested_for |
PD-L1 expression
|
gptkbp:mechanism_of_action |
immune checkpoint inhibition
blocks PD-1 receptor |
gptkbp:potential_indications |
solid tumors
|
gptkbp:publication |
results published in journals
|
gptkbp:recruitment |
active in multiple sites
|
gptkbp:regulatory_compliance |
not yet approved
|
gptkbp:related_products |
submitted to FDA
under clinical investigation |
gptkbp:related_to |
immune system
|
gptkbp:research_areas |
immuno-oncology
|
gptkbp:research_focus |
oncology
|
gptkbp:research_institutes |
various academic centers
|
gptkbp:research_output |
ongoing studies
|
gptkbp:research_updates |
provided to participants
|
gptkbp:route_of_administration |
intravenous
|
gptkbp:safety_features |
under investigation
|
gptkbp:safety_measures |
ongoing during trials
|
gptkbp:scientific_goals |
evaluate safety and efficacy
|
gptkbp:service_frequency |
every 2 weeks
|
gptkbp:side_effect |
immune-related adverse events
monitored during trials |
gptkbp:sponsor |
gptkb:Abb_Vie
|
gptkbp:status |
investigational
|
gptkbp:target_audience |
patients with advanced cancer
|
gptkbp:targets |
gptkb:PD-1
|
gptkbp:treatment |
with chemotherapy
assessed by imaging |
gptkbp:used_for |
gptkb:cancer_treatment
|
gptkbp:bfsParent |
gptkb:Upadacitinib
|
gptkbp:bfsLayer |
6
|